Office of Professional Education

Respiratory Medicine Updates: A Virtual Clinical Community 

Our Next Session is February 8-9, 2022 • CME Credit for Zoom Webinar and Twitter Chat participants

Article: Leukocyte Telomere Length and Mycophenolate Therapy in Chronic Hypersensitivity Pneumonitis. Eur Respir J. 2021 Mar 4;57(3):2002872. doi: 10.1183/13993003.02872-2020. Print 2021 Mar.

  • Zoom Webinar with CME credit: REGISTER.
    • Tuesday, February 8, 2022
    • 11:30 am (PT) / 12:30 pm (MT) / 1:30 pm (CT) / 2:30 pm (ET)
    • 30-minutes
    • Expert faculty summarize a journal article and lead an academic and peer discussion with Q&A time.

  • Twitter Chat @NJHealthMedEd with CME credit: Add to Calendar
    • Wednesday, February 9, 2022
    • 6:00 pm (PT) / 7:00 pm (MT) / 8:00 pm (CT) / 9:00 pm (ET)
    • 30-minutes
    • Expert faculty lead the Chat about the article summary to facilitate an academic and peer discussion with Q&A.
    • Go to Twitter, type in #ILDTwitterJC and click on the “Latest” tab
    • Please use this hashtag when posting: #ILDTwitterJC
    • Twitter Chat Instructions
    • Follow us on Twitter @NJHealthMedEd

Previous ILD Journal Club Sessions:

  • December 14-15, 2021
    • December 2021 Article Summary: Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 2019; 381:1718-1727 DOI: 10.1056/NEJMoa1908681. View here.
    • Recorded Zoom Webinar on VuMedi.
  • November 9-10, 2021
    • November 2021 Article Summary: Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med 2021;384:599-609. DOI: 10.1056/NEJMoa2023386. View here.
    • Recorded Zoom Webinar on VuMedi.
  • October 12-13, 2021
    • October 2021 Article Summary: Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. Am J Respir Crit Care Med. 2021 Jan 15;203(2):211-220. doi: 10.1164/rccm.202003-0877OC. View here.
    • Recorded Zoom Webinar on VuMedi.
  • September 14, 2021
    • September 2021 Article Summary: Tocilizumab in systemic sclerosis: a randomized, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. 2020 Oct;8(10):963-974. doi: 10.1016/S2213-2600(20)30318-0. View here.
    • Recorded Zoom Webinar on VuMedi.
  • August 10-11, 2021
    • August 2021 Article Summary: Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomized controlled trial, The Lancet Respiratory Medicine. 2018;6(10):759-770. View here.
    • Recorded Zoom Webinar on VuMedi.

Target Audience:

Pulmonologists, Rheumatologists, Radiologists, Pathologists, Dermatologists, Primary Care Physicians, Physician Assistants, and Nurse Practitioners.


Program Chair:

Matthew Koslow MD

Matthew Koslow, MD
Assistant Professor
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health, Denver, CO


Learning Objectives:

Upon completion of this activity, the participant will be better able to:

  • Apply critical thinking and research analysis in the review of research and guidelines in ILD
  • Utilize increased awareness and understanding of research, evidence and best practices to inform clinical practice in ILD
  • Support an online community of practitioners to share key insights, latest research, and treatment strategies for patients with ILD



For questions, please call the Office of Professional Education at National Jewish Health at 303.398.1000 or 800.844.2305, or email


Accreditation and Designation Statements:

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

National Jewish Health designates each live activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Twitter Chat Sessions
National Jewish Health designates each Other activity (social media discussion) for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.